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microRNAs (miRNAs) are small, non-coding RNAs that
regulate the expression of proteins through speciﬁc target
sites in the corresponding transcripts. These small RNAs may
functionasoncogenesortumorsuppressorsbymodulatingthe
levelsofcriticalproteins,andtheirrelevanceinhumandisease
and therapy is now under intense investigation. The human
genome encodes about 1500 miRNAs that are thought to
regulate more than 30% of protein-coding genes. Individual
miRNAs can target multiple genes and each protein-coding
gene can be regulated byseveral miRNAs, making the analysis
of these networks difﬁcult to explore. In a recent article
published in Molecular Systems Biology, Uhlmann et al (2012)
report a combined strategy to analyze the multiple miRNA–
protein interactions that regulate cell proliferation in response
to epidermal growth factor receptor (EGFR), an oncogenic
pathway highly relevant in breast cancer. This analysis
provides an unprecedented view of the combinatorial effort
of miRNAs to control a signaling pathway at different levels.
As oncogenic pathways are often resistant to the inhibition of
individualregulators,thisanalysisalsoprovidesthemolecular
basis for selecting individual miRNAs, or a set of a few
miRNAs, whose combined activity may be strong enough to
treat breast tumors.
Activation of the EGFR drives a signaling network that can
lead to cell proliferation, survival, angiogenesis, invasion and
metastasis. Aberrant expression or activity of EGFR has been
strongly linked to the etiology of several human epithelial
cancers, including lung, colorectal and breast cancer, among
others (Wheeler et al, 2010). Not surprisingly, the EGFR
pathway is probably the most explored next-generation target
for breast cancer therapy, and several downstream signal
transducers, such as RAS, AKT or CDKs, are also currently
considered as cancer targets (Weickhardt et al, 2010; Wheeler
et al, 2010). The EGFR pathway controls the expression of
several miRNAs (Avraham et al, 2010; Garofalo et al, 2011),
and some transcription factors and cell cycle regulators
downstream of EGFR are known to be regulated by miRNAs
atdifferentlevels(Avrahametal,2010;BuenoandMalumbres,
2011). However, current information is scarce and typically
describes single interactions between a miRNA and a relevant
target transcript. Uhlmann et al (2012) used a genome-wide
library of miRNA mimics to test their effect on the expression
of 26 proteins in the EGFR-driven cell cycle pathway using
reverse-phase protein arrays. Their ﬁndings validated some of
the miRNA–protein interactions already known, such as the
controlofKRASbymiR-143ortheregulationofEGFRbymiR-7
(Chen et al, 2009; Webster et al, 2009). In addition, other
phenotypic interactions were found between 241 miRNAs and
25 EGFR network transcripts, revealing a total of 355 edges
connecting them (Uhlmann et al, 2012).
The high density of connections led the authors to
investigate possible associations among the identiﬁed inter-
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Figure 1 Control of the EGFR pathway and cell cycle entry by miRNAs. The
EGF receptor uses several downstream pathways to drive cell cycle progression.
Similarly, miRNAs simultaneously modulate several of these downstream
pathways to effect cell cycle progression. For instance, miR-124 co-down-
regulates AKT2, p38MAPK and STAT3 to inhibit the EGFR pathway leading to
CDK downregulation, p27
Kip1 upregulation and cell cycle inhibition. miR-147 also
participates in AKT2 downregulation and simultaneously represses Cyclins
(Cyc). These two examples show how a single miRNA can target several
components of a signaling pathway and how two miRNAs can co-regulate the
same target. These data also suggest the therapeutic value of miR-124 and
miR-147 in treating EGFR-dependent tumors. Only a few representative
molecules are shown for clarity.
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analysis, they found that proteins controlling the EGFR-driven
G1/S transition are frequentlyco-regulated by several miRNAs
(Figure1).Forinstance,independentexpressionof19miRNAs
led to the concomitant downregulation of the cyclin-depen-
dentkinase(CDK)4andupregulationofp27
Kip1,aknownCDK
inhibitor, and both events likely contributed to cell cycle
inhibition by these miRNAs (Uhlmann et al, 2012). The fact
that the retinoblastoma protein was also concomitantly
downregulated may seem surprising given the antiprolifera-
tive function of this molecule. The use of reporter assays on
speciﬁc30-UTRsindicatedthatthesechangeswereindirectand
associated with direct co-repression of several EGFR core
proteins. Thus, miR-124 was able to directly downregulate
AKT2, p38MAPK and STAT3, probably resulting in the observed
changesincellcycleregulators(Figure1).miR-124,miR-147and
miR-193a-3p showed the highest score in the network analysis,
andtheirexpressionhasasigniﬁcanteffectin theEGFR pathway
by simultaneously targeting several of its components in several
different cell lines (Uhlmann et al, 2012). As the expression
of these miRNAs ultimately results in cell cycle inhibition,
these three miRNAs may be relevant tumor suppressors by
co-targeting several EGFR network proteins.
The fact that individual miRNAs may target several
components of a single signaling pathway seems reasonably
obvious. However, clear examples of this type of multi-level
regulation are rare in the literature, probably due to current
technical challenges, including difﬁculties in detecting miR-
NA–protein interactions with moderate effects. The study by
Uhlmann et al (2012) now provides an experimental frame-
work to detect multiple interactions in a single pathway that
may be extended to a higher number of proteins or to other
pathways. The analysis of endogenous miRNAs, rather than
overexpressing exogenous sequences, and the separation of
direct from indirect interactions remain as major challenges in
these massive studies.
Afurtherlevelofcomplexitythatneedstobeclariﬁedishow
the combinational effect of several miRNAs can regulate the
levels of a single protein. Although both miR-124 and miR-147
target AKT2 (Uhlmann et al, 2012; Figure 1), the relevance of
this co-regulation deserves further analysis. Is it additive or
simply redundant? Furthermore, the p27
Kip1 family member
p21
Cip1 may be regulated by 28 miRNAs (Wu et al, 2010), and
MYC, a majoroncogene in several pathologies, can be targeted
by nearly a dozen miRNAs with additive effects (Bueno et al,
2011). The fact that miRNA-target sites in many proteins are
notevolutionarilyconserved(Buenoetal,2011;Uhlmannetal,
2012) suggests that the combinatorial effect of several
miRNAs, rather than a single miRNA, may be the critical
factor for modulating the levels of speciﬁc oncogenes.
In general, it seems that individual miRNAs affect the
expression of many proteins, even in the same pathway
(Uhlmannetal,2012),butinarathermildmanner.Inaddition,
one gene can be regulated by several miRNAs (Wu et al, 2010;
Bueno et al, 2011). Researchers need to use new technical
approaches, such as the one reported by Uhlmann et al (2012),
tocharacterizemultiplicity,redundancyandtheadditiveeffect
of miRNAs in these complex networks. These studies could
identify miRNAs that may be efﬁcient in the inhibition of a key
pathway or even in the simultaneous inhibition of several
pathways regulating cell survival and proliferation. The fact
that AKT1 and ERK2, two major kinases in the PI3K and RAS
oncogenic pathways, maybe co-downregulatedby 30miRNAs
(Uhlmann et al, 2012) is certainly a promising starting point
that highlights the therapeutic potential of this approach.
miRNAs seem to function like short, additive or redundant
tweets with multiple targets, and it is now obvious that ‘social’
networking is essential for the effect of these sequences in cell
signaling. We now need to identify the relevant networks and
validate their social utility.
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